Recommendations for the diagnosis and initial evaluation of patients with Waldenström Macroglobulinaemia: A Task Force from the 8th International Workshop on Waldenström Macroglobulinaemia
- PMID: 27378193
- PMCID: PMC5154335
- DOI: 10.1111/bjh.14196
Recommendations for the diagnosis and initial evaluation of patients with Waldenström Macroglobulinaemia: A Task Force from the 8th International Workshop on Waldenström Macroglobulinaemia
Abstract
The diagnosis of Waldenström macroglobulinaemia (WM) can be challenging given the variety of signs and symptoms patients can present. Furthermore, once the diagnosis of WM is established, the initial evaluation should be thorough as well as appropriately directed. During the 8th International Workshop for WM in London, United Kingdom, a multi-institutional task force was formed to develop consensus recommendations for the diagnosis and initial evaluation of patients with WM. In this document, we present the results of the deliberations that took place to address these issues. We provide recommendations for history-taking and physical examination, laboratory studies, bone marrow aspiration and biopsy analysis and imaging studies. We also provide guidance on the initial evaluation of special situations, such as anaemia, hyperviscosity, neuropathy, Bing-Neel syndrome and amyloidosis. We hope these recommendations serve as a practical guidance to clinicians taking care of patients with a suspected or an established diagnosis of WM.
Keywords: Bing-Neel syndrome; Waldenström macroglobulinaemia; amyloidosis; anaemia; hyperviscosity; neuropathy.
© 2016 John Wiley & Sons Ltd.
Conflict of interest statement
JJC received honoraria from Celgene and Pharmacyclics, and research funding from Abbvie, Gilead, Millennium and Pharmacyclics. RGS received honoraria from Bristol-Myers Squibb, Janssen and Takeda and. EH received honoraria from Amgen, Gilead and Janssen. GM received honoraria from GlaxoSmithKline, Janssen and Millennium-Takeda. RGO received honoraria from Celgene, Janssen, Pharmacyclics and Roche, and research funding from Celgene. CT received honoraria and research funding from Janssen and Roche. MAD received honoraria from Amgen, Celgene, Janssen and Novartis. SPT received research funding and/or honoraria from Gilead, Janssen, Onyx and Pharmacyclics. EK received honoraria from Amgen, Janssen and Takeda and. RAK, XL, MM, MCM, EM, SP, MJS, MV have no conflict of interest to disclose.
Similar articles
-
Initial Evaluation of the Patient with Waldenström Macroglobulinemia.Hematol Oncol Clin North Am. 2018 Oct;32(5):811-820. doi: 10.1016/j.hoc.2018.05.008. Epub 2018 Jul 23. Hematol Oncol Clin North Am. 2018. PMID: 30190019 Review.
-
A practical guide to laboratory investigations at diagnosis and follow up in Waldenström macroglobulinaemia: recommendations from the Medical and Scientific Advisory Group, Myeloma Australia, the Pathology Sub-committee of the Lymphoma and Related Diseases Registry and the Australasian Association of Clinical Biochemists Monoclonal Gammopathy Working Group.Pathology. 2020 Feb;52(2):167-178. doi: 10.1016/j.pathol.2019.11.002. Epub 2020 Jan 3. Pathology. 2020. PMID: 31902622 Review.
-
Consensus treatment recommendations from the tenth International Workshop for Waldenström Macroglobulinaemia.Lancet Haematol. 2020 Nov;7(11):e827-e837. doi: 10.1016/S2352-3026(20)30224-6. Lancet Haematol. 2020. PMID: 33091356 Review.
-
Central nervous system involvement by Waldenström macroglobulinaemia (Bing-Neel syndrome): a multi-institutional retrospective study.Br J Haematol. 2016 Mar;172(5):709-15. doi: 10.1111/bjh.13883. Epub 2015 Dec 21. Br J Haematol. 2016. PMID: 26686858 Free PMC article.
-
Treatment of patients with Waldenström macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory Group.Intern Med J. 2017 Jan;47(1):35-49. doi: 10.1111/imj.13311. Intern Med J. 2017. PMID: 28076910
Cited by
-
Pathophysiology and Treatments of Complications of Waldenström's Macroglobulinemia.Clin Hematol Int. 2024 Oct 7;6(4):11-18. doi: 10.46989/001c.124268. eCollection 2024. Clin Hematol Int. 2024. PMID: 39417016 Free PMC article.
-
Successful treatment of a CLL associated IgM hyper-viscosity syndrome: A rare case.Leuk Res Rep. 2024 Aug 22;22:100479. doi: 10.1016/j.lrr.2024.100479. eCollection 2024. Leuk Res Rep. 2024. PMID: 39281974 Free PMC article.
-
Bruton Tyrosine Kinase Inhibition: an Effective Strategy to Manage Waldenström Macroglobulinemia.Curr Hematol Malig Rep. 2024 Jun;19(3):120-137. doi: 10.1007/s11899-024-00731-0. Epub 2024 Mar 27. Curr Hematol Malig Rep. 2024. PMID: 38536576 Review.
-
The performance and applied value of 18F-FDG PET/CT imaging in Waldenstrom macroglobulinemia.Am J Nucl Med Mol Imaging. 2023 Oct 20;13(5):217-224. eCollection 2023. Am J Nucl Med Mol Imaging. 2023. PMID: 38023819 Free PMC article.
-
Laboratory and Clinical Settings of Heavy/Light Chain (HLC) Assays in the Management of Monoclonal Gammopathies and Multiple Myeloma.J Pers Med. 2023 Apr 27;13(5):743. doi: 10.3390/jpm13050743. J Pers Med. 2023. PMID: 37240913 Free PMC article. Review.
References
-
- Swerdlow SH, Berger F, Pileri SA, et al. Lymphoplasmacytic lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC; 2008. pp. 194–195.
-
- Castillo JJ, Olszewski AJ, Cronin AM, et al. Survival trends in Waldenstrom macroglobulinemia: an analysis of the Surveillance, Epidemiology and End Results database. Blood. 2014;123:3999–4000. - PubMed
-
- Castillo JJ, Olszewski AJ, Kanan S, et al. Overall survival and competing risks of death in patients with Waldenstrom macroglobulinaemia: an analysis of the Surveillance, Epidemiology and End Results database. Br J Haematol. 2015;169:81–89. - PubMed
-
- Morel P, Duhamel A, Gobbi P, et al. International prognostic scoring system for Waldenstrom macroglobulinemia. Blood. 2009;113:4163–4170. - PubMed
-
- Treon SP. How I treat Waldenstrom macroglobulinemia. Blood. 2015;126:721–732. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
